Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.004
Neutral
RSI(14)
68.961
Neutral
STOCH(KDJ)(9,3,3)
76.063
Buy
ATR(14)
1.071
High Vlolatility
CCI(14)
133.257
Buy
Williams %R
21.450
Buy
TRIX(12,20)
0.405
Sell
StochRSI(14)
60.029
Sell
AstraZeneca PLC
AZN81.700USD
-0.080-0.10%
Close 09/05, 16:00（ET）Quotes delayed by 15 min
253.38BMarket Cap
30.55P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Currency: USD Updated：2025-09-05Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
13
analysts
Buy
Current Rating
100.260
Target Price
+22.60%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology firm headquartered at the Cambridge Biomedical Campus in Cambridge, UK. The company boasts a diverse portfolio of products aimed at treating major diseases in areas such as oncology, cardiovascular health, gastrointestinal issues, infections, neuroscience, respiratory conditions, and inflammation.
Founded in 1999 through the merger of Swedish Astra AB and British Zeneca Group, it includes offerings for both primary and specialty care, coverage for rare diseases, and maintains a strong global presence across various regions. Since the merger, AstraZeneca has consistently ranked among the largest pharmaceutical companies worldwide and has executed numerous corporate acquisitions, such as Cambridge Antibody Technology, MedImmune, Spirogen, and Definiens. Its research and development efforts are concentrated in three strategic centers: Cambridge in the UK, Gothenburg in Sweden, and Gaithersburg in Maryland, US.
AstraZeneca’s corporate lineage can be traced back to 1913, when Astra AB was established by a significant group of physicians and pharmacists in Södertälje. Throughout the 20th century, Astra AB evolved into Sweden's largest pharmaceutical company. Its British counterpart, Zeneca PLC, was created in 1993 when ICI divested its pharmaceuticals division; six years later, Astra AB and Zeneca PLC merged, designating the United Kingdom as the headquarters.
AstraZeneca's primary listing is on the London Stock Exchange, where it is part of the FTSE 100 Index, alongside a secondary listing on Nasdaq Stockholm. It is also traded on the American Nasdaq and is included in the Nasdaq-100 index. AstraZeneca ranks among the pharmaceutical companies globally with one of the highest market capitalizations.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 21.92% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 113.96.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 68.32%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 68.32%.
Undervalued
The company’s latest PE is 30.54, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 530.44M shares, decreasing 3.96% quarter-over-quarter.
Held by PRIMECAP Management
Star Investor PRIMECAP Management holds 41.20M shares of this stock.
Financial Health
Currency: USD Updated：2025-09-05The company's current financial score is 7.66, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 13.59B, representing a year-over-year increase of 7.17%, while its net profit experienced a year-over-year increase of 33.82%.
Score
Financials
7.46
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
7.53
Operational Efficiency
7.66
Growth Potential
8.03
Shareholder Returns
7.62
Company Valuation
Currency: USD Updated：2025-09-05The company’s current valuation score is 4.80, which is higher than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is 29.88, which is 30.34% below the recent high of 38.95 and -11.67% above the recent low of 33.37.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 22/686
No Data
Earnings Forecast
Currency: USD Updated：2025-09-05The company’s current earnings forecast score is 8.43, which is higher than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for AstraZeneca PLC is 89.00, with a high of 232.41 and a low of 67.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
13
analysts
Buy
Current Rating
100.260
Target Price
+22.72%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
179
Total
5
Median
8
Average
Company name
Ratings
Analysts
AstraZeneca PLC
AZN
13
Biogen Inc
BIIB
36
Amgen Inc
AMGN
34
Vertex Pharmaceuticals Inc
VRTX
33
Alnylam Pharmaceuticals Inc
ALNY
33
Eli Lilly and Co
LLY
31
1
2
3
...
36
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated：2025-09-05The company’s current price momentum score is 9.28, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 83.31 and the support level at 74.78, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
81.136
Buy
MA10
80.628
Buy
MA20
79.223
Buy
MA50
74.702
Buy
MA100
72.541
Buy
MA200
71.302
Buy
Institutional Confidence
Currency: USD Updated：2025-09-05The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 17.10%, representing a quarter-over-quarter decrease of 0.36%. The largest institutional shareholder is PRIMECAP Management, holding a total of 41.20M shares, representing 1.33% of shares outstanding, with 0.44% increase in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
Wellington Management Company, LLP
Capital International Investors
T. Rowe Price International Ltd
Managed Account Advisors LLC
Fidelity Management & Research Company LLC
Sanders Capital, LLC
Putnam Investment Management, L.L.C.
1
2
Risk Assessment
Currency: USD Updated：2025-09-05The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 5.93, which is higher than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is 0.38. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.38
VaR
+2.40%
240-Day Maximum Drawdown
+20.58%
240-Day Volatility
+25.54%
Return
Best Daily Return
60 days
+3.58%
120 days
+3.58%
5 years
+6.62%
Worst Daily Return
60 days
-4.57%
120 days
-7.39%
5 years
-8.83%
Sharpe Ratio
60 days
+2.02
120 days
+0.64
5 years
+0.56
Risk Assessment
Maximum Drawdown
240 days
+20.58%
3 years
+27.87%
5 years
+27.87%
Return-to-Drawdown Ratio
240 days
+0.17
3 years
+0.60
5 years
+0.35
Skewness
240 days
-1.03
3 years
-0.72
5 years
-0.56
Volatility
Realised Volatility
240 days
+25.54%
5 years
+24.89%
Standardised True Range
240 days
+1.66%
5 years
+1.47%
Downside Risk-Adjusted Return
120 days
+82.73%
240 days
+82.73%
Maximum Daily Upside Volatility
60 days
+19.20%
Maximum Daily Downside Volatility
60 days
+19.25%
Liquidity
Average Turnover Rate
60 days
+0.28%
120 days
+0.32%
5 years
--
Turnover Deviation
20 days
-30.14%
60 days
-17.54%
120 days
-5.43%
Peer Comparison
Currency: USD Updated：2025-09-05AstraZeneca PLC
AZN
7.09 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
7.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
7.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stoke Therapeutics Inc
STOK
7.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
7.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
7.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.
